Document:

EXECUTIVE
EMPLOYMENT AGREEMENT

 

 

TH
IS EXECUTIVE EMPLOYMENT AGREEMENT ("Agreement") is made and entered
into as of September 30, 2013 (the "Effective Date"), by and between
MusclePharm Corporation, a Nevada Corporation (the "Company"), and Richard
Estalella, an individual ("Executive").The
Company and Executive are sometimes referred to herein as a "party" or
collectively as the "parties."

 

RECITALS

 

 

WHEREAS,
Executive is willing to continue to be employed by the Company and provide services to the Company under the terms and conditions
stated herein, as of April 29, 2013 (the “Start Date”); and

 

WHEREAS,
the Company and Executive now mutually desire to enter into this Agreement as approved by the Board.

 

NOW,
THEREFORE, in consideration of the foregoing, of the mutual covenants and agreements herein contained, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, agree
as follows:

 

		1.	Employment and Duties

 

1.1          
Employment. The Company hereby agrees to employ Executive as Chief Operating Officer of the Company and Executive
hereby accepts such employment as of the Start Date pursuant to the terms, covenants and conditions set forth herein. Executive
shall report directly to the Chief Executive Officer ("CEO") of the Company.

 

1.2          
Duties. Executive shall have the overall responsibility as the Chief Operating Officer of the Company and its operations,
and shall perform all duties and responsibilities and have such powers which are commonly incident to the offices and positions
held by him, as well as any additional responsibilities and authority as may be from time to time assigned or delegated to him
by the CEO and the Board. Executive shall perform the duties assigned to him to the best of his ability and in a manner satisfactory
to the Company.

 

1.3          
Time and Efforts. Executive will devote his full business time, efforts, attention, and energies to the business
of the Company and to the performance of Executive's duties hereunder during the Term (as defined below), and will not engage in
any other business, profession or occupation for compensation or otherwise which would conflict or interfere with the performance
of such services, either directly or indirectly, without the prior written consent of the Company; provided that, nothing herein
shall preclude Executive from (i) continuing to serve on any board of directors or trustees of any "not
for profit" organization, (ii) being involved in charitable activities, or (iii) managing
his personal and family passive investments; provided, further that, in each case, and in the aggregate, such activities shall
not materially conflict with or interfere with the performance of Executive's duties hereunder or conflict with his duty ofloyalty
and/or fiduciary duties owed to the Company.

 

    	-1-

    	 

    

		2.	Term

 

Unless
earlier terminated as provided in Section 5, the Company shall employ Executive in the capacity set forth herein for a term commencing
on the Start Date and ending on December 31, 2015. Such period, as may be terminated earlier or extended, to be referred to herein
as the "Term".

 

		3.	Compensation

 

As
compensation for the services to be rendered by Executive for and on behalf of the Company hereunder, Executive shall be entitled
to the following:

 

3.1           
Base Salary. Executive shall receive an annual base salary of $250,000. Salary
payments shall be subject to all applicable federal and state withholding, payroll, and
other taxes, and all applicable deductions for benefits as may be required by law or Executive's authorization. Executive's Base
Salary will be reviewed at least annually by the Compensation Committee (the "Committee") of the Board and may
be increased at the discretion of the Committee.

 

3.2          
Bonus. In addition to Base Salary, Executive shall be eligible to receive one
or more cash bonuses to be determined by the Committee in its sole discretion based on performance criteria to be adopted by the
Committee, with a potential bonus pool of $250,000 per year. Any such bonus or bonuses shall be subject to all applicable federal
and state withholding, payroll and other taxes, and all applicable deductions for benefits as may be required by law, and shall
be paid to Executive no later than the 15th day of the third calendar month following the end of the fiscal year (or other performance
period) with respect to which the bonus relates.

 

3.3           
Equity Compensation.Executive may, as determined by the Committee in its
discretion, periodically receive grants of stock options, restricted stock or other equity-related awards from the Company's various
equity compensation plans, subject to the terms and conditions thereof.

 

3.4           
Compensation Committee. Any bonus and any equity consideration to be provided
to Executive shall be reviewed and determined by the Committee on an annual basis to set performance criteria for purposes of compliance
with the requirements of Section 162(m) of the Internal Revenue Code of 1986, as amended (the
"Code").

 

3.5         
Expenses. The Company shall reimburse Executive for all reasonable business expenses
incurred by Executive in the performance of his duties, provided that Executive provides adequate documentation required by law
and by the policies and procedures of the Company, as adopted and amended from time to time, provided that in no event shall Executive
submit any required documentation later than sixty (60) days after the end of the calendar year in which such expense was incurred.
Any such reimbursement shall be made as soon as reasonably practicable but in no event later than the 15th day of the third month
following the calendar year in which the applicable expense was incurred. Executive acknowledges and agrees that all such expenses
will be subject to the oversight of the Audit
Committee of the Board. The Company shall also provide Executive with a laptop computer and cell phone for his business use during
the Term.

    	-2-

    	 

    

 

3.6          
Vacation. Executive shall be entitled to accrue four (4) weeks of paid vacation each year pursuant to the terms and
provisions of the Company's vacation leave policies as in effect from time to time. Although unused vacation may be carried over
from year to year, the maximum cap on accrual shall be equal to one hundred fifty percent (150%) of the annual accrual.

 

3.7           
Benefits.Executive shall be entitled to participate in and receive all benefits made available by the Company
to its executive officers, subject to and on a consistent basis with the terms, conditions and overall administration of such plans
and arrangements, including without limitation, medical, dental, vision, life and disability insurance plans and coverage, and
defined benefit, defined contribution or other 401 (k) program, including all Company matching provisions.

 

		4.	Confidential Information; Non-Compete; Non-Solicitation

 

4.1           
Confidential Information.Executive acknowledges that, during the course of his employment, he will have access
to and will receive information which constitutes trade secrets, is of a confidential nature, is of significant value to the Company
and/or is a foundation on which the business of the Company is predicated. With respect to all such Confidential Information (as
defined hereafter), Executive agrees, during the Term and thereafter, not to disclose such Confidential Information to any person
other than an employee, counsel, or advisor of the Company or a person to whom disclosure is reasonably necessary or appropriate
in connection with the performance by Executive of his duties hereunder nor to use such Confidential Information for any purpose
other than the performance of his duties hereunder. For purposes of this Agreement, the term "Confidential
Information" includes all data or material
(regardless of form) with respect to the Company or any of its assets, prospects, business activities, officers, directors, employees,
borrowers, or clients which is: (a) a trade secret, as defined by the Uniform Trade Secrets Act; (b) provided, disclosed, or delivered
to Executive by the Company, any officer, director, employee, agent, attorney, accountant, consultant, or other person or entity
employed by the Company in any capacity, any client, borrower, advisor, or business associate of the Company, or any public authority
having jurisdiction over the Company or any business activity conducted by the Company; or (c) produced, developed, obtained or
prepared by or on behalf of Executive or the Company (whether or not such information was developed in the performance of this
Agreement). Notwithstanding the foregoing, the term "Confidential Information"
shall not include any information, data, or material which, at the time of disclosure or use, was generally available to the public
other than by a breach of this Agreement, was available to the party to whom disclosed on a non-confidential basis by disclosure
or access provided by the Company or a third party without breaching any obligations of the Company or such third party, or was
otherwise developed or obtained legally and independently by the person to whom disclosed without a breach of this Agreement. This
Section 4.1 shall not preclude Executive from disclosing Confidential Information if compelled to do so by law or valid legal process,
provided that if Executive believes Executive is so compelled by law or valid legal process, Executive will notify the Company
in writing sufficiently in advance of any such disclosure to allow the Company the opportunity to defend, limit, or otherwise protect
its interests against such disclosure unless such notice is prohibited by law. The rights and obligations of the parties under
this paragraph shall survive the expiration or termination of this Agreement for any reason.

    	-3-

    	 

    

4.2          
Non-Competition. As part of the consideration for the compensation and benefits
to be paid to Executive hereunder, and in order to protect the Confidential Information, business goodwill, and business opportunities
of the Company, Executive agrees that, during the Term and for a period of six (6) months after the termination of Executive's
employment and this Agreement, he will not, directly or indirectly, engage in or become interested financially in, as a principal,
employee, partner, contractor, shareholder, agent, manager, owner, advisor, lender, guarantor, officer, or director, any business
(other than the Company) that is engaged in the nutritional supplement industry and/or related products; provided, however, that
Executive shall be entitled to continue to invest in stocks, bonds, or other securities in any such business (without otherwise
participating in such business) if: (a) such stocks, bonds, or other securities are listed on any United States securities exchange
or are publicly traded in an over the counter market; and such investment does not exceed, in the case of any capital stock of
any one issuer, five percent of the issued and outstanding capital stock, or in the case of bonds or other securities, five percent
of the aggregate principal amount thereof issued and outstanding; or (b) such investment is completely passive and no control or
influence over the management or policies of such business is exercised.

 

4.3          
Non-Solicitation.Executive agrees that he will not, at any time during the
Term, or at any time within twelve (12) months after the termination of his employment, for his own account or benefit or for the
account or benefit of any other person, firm or entity, directly or indirectly, solicit for employment any employee of the Company
(or any person who was an employee of the Company in the 90-day period before such solicitation) or induce any employee of the
Company (or any person who was an employee of the Company in the 90-day period before such inducement) to terminate his employment
with the Company. Notwithstanding the above, the restrictions relating to persons employed in the 90-day period referenced in the
parentheticals in the immediately preceding sentence shall not apply to a person who was a party to an employment agreement with
the Company and who terminates his employment for Good Reason or is terminated by the Company without Cause. The rights and obligations
of the parties under this Section 4.3 shall survive the expiration or termination of this Agreement for any reason.

 

4.4           
Proprietary Matters. Executive expressly agrees that any and all improvements,
inventions, discoveries, processes, or know-how that are generated or conceived by Executive during the Term, whether conceived
during Executive's regular working hours or otherwise, will be the sole and exclusive property of the Company. Whenever requested
by the Company (either during the Term or thereafter), Executive will assign or execute any and all applications, assignments and/or
other documents, and do all things which the Company reasonably deems necessary or appropriate, in order to permit the Company
to: (a) assign and convey, or otherwise make available to the Company, the sole and exclusive right, title, and interest in and
to said improvements, inventions, discoveries, processes or know-how; or (b) apply for, obtain, maintain, enforce and defend patents,
copyrights, trade names, or trademarks of the United States or of foreign countries for said improvements, inventions, discoveries,
processes, or know-how. However, the improvements, inventions, discoveries, processes, or know-how generated or conceived by Executive
and referred to in this Section 4.4 (except those which may be included in the patents, copyrights, or registered trade names or
trademarks of the Company) will not be exclusive property of the Company at any time after having been disclosed or revealed or
have otherwise become available to the public or to a third party on a non-confidential basis other than by a breach of this Agreement,
or after they have been independently developed or discussed without a breach of this Agreement by a third party who has no obligation
to the Company.

    	-4-

    	 

    

The rights and obligations of the
parties under this Section 4.4 shall survIVe the expiration or te1mination of this Agreement for any reason.

 

4.5           
Injunctive Relief. Executive acknowledges and agrees that any violation of Sections 4.1, 4.2, 4.3 or 4.4 of this
Agreement would result in irreparable harm to the Company and, therefore, agrees that, in the event of an actual, suspected, or
threatened breach of Sections 4.1, 4.2, 4.3 or 4.4 of this Agreement, the Company shall be entitled to an injunction restraining
Executive from committing or continuing such actual, suspected or threatened breach. The parties acknowledge and agree that the
right to such injunctive relief shall be cumulative and shall not be in lieu of, or be construed as a waiver of the Company's right
to pursue, any other remedies to which it may be entitled in law or in equity. The parties agree that for purposes of Sections
4.1, 4.2, 4.3 and 4.4 of this Agreement, the term "Company" shall
include the Company and its affiliates.

 

		5.	Termination

 

Executive's
employment by the Company and this Agreement may be terminated before the expiration of the Term, without breach of this Agreement,
in accordance with the provisions set forth below:

 

5.1          
Termination by the Company for Cause. The Company may terminate Executive's employment and this Agreement for Cause
(as defined below), but only after: (i) giving Executive written notice of the failure or conduct which the Company believes to
constitute Cause; and (ii) with respect to elements (a) through (e) below, providing Executive a reasonable opportunity, and in
no event more than twenty (20) days, to cure such failure or conduct, unless the Board determines in its good faith judgment that
such failure or conduct is not reasonably capable of being cured. In the event Executive does not cure the alleged failure or conduct
within the time frame provided for such cure by the Company, the Company shall send him written notice specifying the effective
date of termination. The failure by the Company to set forth in the notice referenced in this Section 5.1 any fact or circumstance
which contributes to a showing of Cause shall not waive any right of the Company to assert, or preclude the Company from asserting,
such fact or circumstance in enforcing its rights hereunder. For purposes of this Agreement, the term "Cause"
means:

 

(a)           conviction
of a felony or a crime involving fraud or moral turpitude; or

 

(b)           theft,
material act of dishonesty or fraud, intentional falsification of any employment or Corporation records, or commission of any criminal
act which impairs participant’s ability to perform appropriate employment duties for the Corporation; or

 

(c)           intentional
or reckless conduct or gross negligence materially harmful to the Corporation or the successor to the Corporation after a Change
in Control , including violation of a non-competition or confidentiality agreement; or

 

(d)           willful
failure to follow lawful instructions of the person or body to which participant reports; or

 

(e)           gross
negligence or willful misconduct in the performance of participant’s assigned duties.  Cause shall not include
mere unsatisfactory performance in the achievement of participant’s job objectives.

 

    	-5-

    	 

    

 

If
the Company terminates Executive's employment for Cause, then Executive shall be entitled to receive the payments and benefits
set forth in Section 6.1 below.

 

The Company
may suspend Executive with pay pending an investigation authorized by the Company or a governmental authority or a determination
whether Executive has engaged in acts or omissions constituting Cause, and such paid suspension shall not constitute Good Reason
or a termination of Executive’s employment.

 

		5.2	Termination by the Company Without Cause.

 

(a)            The
Company may terminate the employment of Executive and this Agreement at any time during the Term of this Agreement without
Cause by giving Executive written notice of such termination, to be effective thirty (30) days following the giving of such
written notice, in which case Executive shall receive the compensation, severance, and benefit continuation required by
Section 6.3 below; provided, however, that if Company terminates Executive's employment without Cause during the
Protection Period (as defined below), then Executive shall be entitled to receive the payments and benefits set forth in
Section 6.4 below.

 

(b)           
For purposes of this Agreement, the term "Protection
Period" means the period of time commencing
on the date of the first occurrence of a Change in Control (as defined below in Section 5.2(c)) and continuing until the earlier
of the (i) the second anniversary of the first occurrence of the Change in Control and (ii) the Term of this Agreement; and the
six (6) month period prior to such Change in Control date if the Executive is terminated without Cause or terminates for Good Reason
and in either case such termination (x) was requested by the third party that effectuates the Change in Control, or (y) occurs
in connection with or in anticipation of a Change in Control, it being agreed that any such action taken following stockholder
approval of a transaction which if consummated would constitute a Change in Control shall be deemed to be in anticipation of a
Change in Control provided such transaction is actually consummated.

 

(c)           
For purposes of this Agreement, the term "Change in Control" means
the happening of any of the following events: 

 

i.         a tender offer (or series of related offers) shall be made and consummated for the ownership of 50% or more of the outstanding
voting securities of the Company, unless as a result of such tender offer more than 50% of the outstanding voting securities of
the surviving or resulting corporation shall be owned in the aggregate by the stockholders of the Company (as of the time immediately
prior to the commencement of such offer), any employee benefit plan of the Company or its subsidiaries, and their affiliates;

 

ii.        the Company shall be merged or consolidated with
another corporation, unless as a result of such merger or consolidation more than 50% of the outstanding voting securities of the
surviving or resulting corporation shall be owned in the aggregate by the stockholders of the Company (as of the time immediately
prior to such transaction), any employee benefit plan of the Company or its subsidiaries, and their affiliates;

 

(iii)       the Company shall sell substantially all of its
assets to another corporation that is not wholly owned by the Company, unless as a result of such sale more than 50% of such assets
shall be owned in the aggregate by the stockholders of the Company (as of the time immediately prior to such transaction), any
employee benefit plan of the Company or its subsidiaries and their affiliates; or

 

    	-6-

    	 

    

 

(iv)       a person (as defined below) shall acquire 50% or
more of the outstanding voting securities of the Company (whether directly, indirectly, beneficially or of record), unless as a
result of such acquisition more than 50% of the outstanding voting securities of the surviving or resulting corporation shall be
owned in the aggregate by the stockholders of the Company (as of the time immediately prior to the first acquisition of such securities
by such person), any employee benefit plan of the Corporation or its subsidiaries, and their affiliates.

 

5.3        
Termination by the Company Due to Inability to Perform or Death. Executive's employment and this Agreement may be
terminated by the Company as follows:

 

(a)         
To the extent permitted by law, upon thirty (30) days' notice to Executive in the event of Executive's Inability to Perform.
For this purpose, the term "Inability to Perform" means and shall be deemed to have occurred if Executive has
been determined under the Company's long term disability plan to be eligible for long-term disability benefits or, in the event
the Company does not maintain such a plan or in the absence of Executive's participation in or application for benefits under such
a plan, such term shall mean the inability of Executive, despite any reasonable accommodation required by law, due to bodily injury
or disease or any other physical or mental incapacity, to perform the services required hereunder for a period of ninety (90) consecutive
days; or

 

		(b)	Immediately upon the death of Executive.

 

5.4        
Termination by Executive for Good Reason. Executive may terminate his employment and this Agreement at .any
time for Good Reason (as defined below). A termination of employment and this Agreement by Executive for Good Reason shall entitle
Executive to payments and other benefits as specified in Section 6.3, unless such termination occurs during the Protection Period
in which case the payments and benefits in Section 6.4 shall apply. For purposes of this Agreement, the term "Good Reason"
means, subject to the notice and cure provisions herein, any of the following actions if taken without Executive's prior written
consent: (a) the assignment to the Executive of any duties inconsistent with the position in the Corporation that Executive held
immediately prior to the assignment; (b) a Change of Control resulting in a significant adverse alteration in the status or conditions
of Executive’s participation with the Corporation or other nature of Exeucutive’s responsibilities from those in effect
prior to such Change of Control, including any significant alteration in Holder’s responsibilities immediately prior to such
Change in Control; (c) the failure by the Company to continue to provide the Executive with benefits substantially similar to those
enjoyed by the Executive prior to such failure; or (d) any other action or inaction that constitutes a material breach by the Company
of this Agreement. To exercise the option to terminate employment for Good Reason, Executive must provide written notice to the
Company of Executive's belief that Good Reason exists within sixty (60) days of the initial existence of the Good Reason condition,
and that notice shall describe in reasonable detail the condition(s) believed to constitute Good Reason. The Company then shall
have thirty (30) days to remedy the Good Reason condition(s). If not
remedied within that 30-day period or if the Company notifies Executive that it does not intend to cure such condition(s) before
the end of that 30-day period, Executive may submit a notice of termination to the Company; provided, however, that the notice
of termination invoking Executive's option to terminate employment for Good Reason must be given no later than one hundred (100)
days after the date the Good Reason condition first arose; otherwise, Executive shall be deemed to have accepted the condition(s),
or the Company's correction of such condition(s), that may have given rise to the existence of Good Reason.

 

    	-7-

    	 

    

 

5.5         Termination
by Executive Without Good Reason. Executive may also terminate his employment and this Agreement without Good Reason by
providing at least ninety (90) days' written notice of such termination to the Company. In the event of a
termination pursuant to this Section 5.5, Executive shall be entitled to payments and other benefits as specified in Section
6.1 below. At the Company's option, the Company may accelerate the date of Executive's termination of employment by paying to
Executive the Base Salary and value of the benefits that Executive would have received during the period by which the date of
termination is so accelerated and such acceleration shall not change the characterization of the termination by Executive as
a termination without Good Reason .

 

5.6        
Return of Confidential Information and Company Property. Upon termination of
Executive's employment for any reason, Executive shall immediately return all Confidential Information and other Company property
to the Company.

 

		6.	Effect of Termination

 

6.1          
Termination by the Company for Cause or Termination by Executive Without Good Reason.
In the event Executive's employment and this Agreement are terminated pursuant to Sections 5.1 or 5.5 above:

  

(a)           
The Company shall pay to Executive, or his representatives, on the date of termination of employment only that portion of
the Base Salary provided in Section 3.1 that has been accrued through the date of termination, any accrued but unpaid vacation
pay provided in Section 3.7, any accrued benefits provided in Section 3.8, and any expense reimbursements due and owing to Executive
as of the date of termination; and

 

(b)         
Executive shall not be entitled to: (i) any other salary or compensation; (ii) any bonus pursuant to Section 3.2; (iii)
any equity consideration pursuant to Section 3.3; nor (iv) any benefits pursuant to Section 3.6; and

 

(c)           
Executive shall return the laptop computer and cellular telephone provided in Section 3.6 within five (5) business days
of the date of termination.

 

6.2        
Termination by the Company Due to Executive’s Inability to Perform or Death.

 

In the event
Executive's employment and this Agreement are terminated pursuant to Section 5.3 above, the Company shall pay to Executive, or
his representatives, all of the following:

 

(a)           
The payments, if any, referred to in Section 6.1(a) above as of the date of termination; and

 

(b)           
Subject to compliance with Section 409A of the Code, an amount equal to the greater of (i) one hundred percent (100%) of
Executive's target bonus for the year in which the date of termination occurs or (ii) a bonus for such year as may be determined
by the Committee in its sole discretion. This amount shall be paid in the form of a lump sum, less applicable statutory deductions
and withholdings, as soon as practicable after the date of termination, but no later than March 15 of the year immediately following
the year in which the date of termination occurs; and

 

(c)           
For a termination due to Inability to Perform only, and provided that Executive or his representative signs a Release (as defined
in Section 17), then the Company shall pay Executive a severance equal to six (6) months of Executive's Base Salary at the time
of termination. This severance amount shall be paid to Executive in equal regular installments
over the six (6) month period pursuant to the Company's regular payroll periods, less applicable statutory deductions and tax
withholdings. The first installment shall be paid to Executive on the first payroll period after the date of termination and after
the effective date of the Release; and

 

    	-8-

    	 

    

 

(d)           
Should Executive or his representatives timely elect to continue coverage under a group
health insurance plan sponsored by the Company or one of its affiliates and timely make the premium payments, reimburse Executive
on a monthly basis for the cost of continued coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA")
or other applicable law for Executive and any eligible dependents until the earlier of (i) the date Executive is no
longer entitled to continuation coverage under COBRA or (ii) for twelve (12) months after the date of termination.

 

6.3        
Termination by the Company Without Cause and Without a Change in Control or by Executive
for Good Reason Without a Change in Control. In the event Executive's employment is terminated pursuant to Sections 5.2 or
5.4 above at any time in which there has not been a qualifying Change in Control termination, the Company shall pay Executive on
the date of termination the payments referred to in Section 6.1(a) above, and provided that Executive signs a Release (as defined
in Section 17), Executive shall also receive all of the following:

 

(a)            
A severance package equal to the lesser of (i) nine (9) months of Executive's Base Salary
at the time of termination and (ii) the Base Salary remaining under the Term of this Agreement. This severance amount shall be
paid to Executive in equal regular installments over the three (3) month period pursuant to the Company's regular payroll periods,
less applicable statutory deductions and tax withholdings. The first installment shall be paid to Executive on the first payroll
period after the date of termination and after the effective date of the Release; and

 

(b)           
Subject to compliance with Section 409A of the Code, an amount equal to the greater
of (i) (A) if the date of termination occurs between January 1 and June 30, then twenty-five percent (25%) of Executive's target
bonus for the year in which the date of termination occurs or (B) if the date of termination occurs between July 1 and December
31, then fifty percent (50%) of Executive's target bonus for the year in which the date of termination occurs; and (ii) a bonus
for such year as may be determined by the Committee in its sole discretion. This amount shall be paid in the form of a lump sum,
less applicable statutory deductions and withholdings, as soon as practicable after the date of termination, but no later than
March 15 of the year immediately following the year in which the date of termination occurs;

 

(c)            
Should Executive or his representatives timely elect to continue coverage under a group
health insurance plan sponsored by the Company or one of its affiliates and timely make the premium payments, reimburse Executive
on a monthly basis for the cost of continued coverage under the COBRA for Executive and any eligible dependents until the earlier
of (i) the date Executive is no longer entitled to continuation coverage under COBRA or (ii) for twelve (12) months after the date
of termination; and

 

(d)           
Unless otherwise provided in the equity award agreement, all stock options and other
stock incentive awards held by Executive will become fully vested and immediately exercisable and all restrictions on any restricted
stock held by Executive will be removed; provided, however, Executive shall not be released from the black-out periods for the
next financial reporting quarter following
the date of termination or Securities Exchange Act of 1934, as amended (the "Exchange Act"),
trading obligations typically required for an executive in this position.

    	-9-

    	 

    

 

6.4        
Termination by the Company Without Cause After a Change in Control or by Executive
for Good Reason After a Change in Control.In the event Executive's employment is terminated pursuant to Sections 5.2 or
5.4 above during the Protection Period, the Company shall pay Executive on the date of termination the payments referred to in
Section 6.l (a) above, and provided that Executive signs a Release (as defined in Section 17), Executive shall also receive all
of the following:

 

(a)            
Subject to compliance with Section 409A of the Code, a severance package equal to one
year of Executive's Base Salary immediately prior to the Change in Control. This severance amount shall be paid to Executive in
equal regular installments over a 12-month period pursuant to the Company's regular payroll periods, less applicable statutory
deductions and tax withholdings. The first installment shall be paid to Executive on the first payroll period after the date of
termination and after the effective date of the Release ; and

 

(b)           
Subject to compliance with Section 409A of the Code, an amount equal to the greater
of (i) one hundred percent (100%) of Executive's target bonus for the year in which the date of termination occurs or (ii) a bonus
for such year as may be determined by the Committee in its sole discretion. This amount shall be paid in the form of a lump sum,
less applicable statutory deductions and withholdings, as soon as practicable after the date of termination, but no later than
March 15 of the year immediately following the year in which the date of termination occurs; and

 

(c)            
A one-time cash payment of five hundred thousand dollars ($500,000.00), less applicable
statutory deductions and tax withholdings, to be paid within thirty (30) days of the date of termination; and

 

(d)           
Should Executive or his representatives timely elect to continue coverage under a group
health insurance plan sponsored by the Company or one of its affiliates and timely make the premium payments ,
reimburse Executive on a monthly basis for the cost of continued coverage under the COBRA for
Executive and any eligible dependents until the earlier of (i) the date Executive is no longer entitled to continuation coverage
under COBRA or (ii) for twelve (12) months after the date of termination; and

 

(e)           
All stock options and other incentive awards held by Executive will become fully vested
and immediately exercisable and all restrictions on any restricted stock held by Executive will be removed; provided, however,
Executive shall not be released from the black-out periods for the next financial quarter following
the date of termination or Exchange Act, trading obligations typically required for an executive in this position.

 

		7.	Successors and Assigns

 

This
Agreement is personal in nature, and neither this Agreement
nor any part of any obligation herein shall be assignable by Executive. The Company shall be entitled to assign this Agreement
to any affiliate of the Company or any person or entity that assumes the ownership and control of the business of the Company.
This Agreement shall inure to the benefit of and shall be binding upon the parties and their successors and assigns.

    	-10-

    	 

    

		8.	Severability

 

Should
any term, provision, covenant or condition of this Agreement be held to be void or invalid, the same shall not affect any other
term, provision, covenant or condition of this Agreement, but such remainder shall continue in full force and effect as though
each such voided term, provision, covenant, or condition is not contained herein.

 

		9.	Governing Law and Venue

 

This
Agreement shall be governed by and construed in accordance with the laws of the State of Colorado, excluding its choice-of-law
principles. Subject to Sections 4.5 and 10, and without in any way limiting the applicability of binding arbitration, each of the
parties submits to the exclusive jurisdiction of any state or federal court sitting in Denver, Colorado in any action or proceeding
arising out of or relating to this Agreement and further agrees that all claims in respect of the action or proceeding may be heard
and determined in any such court to the extent that any court proceeding is necessary in connection with Sections 4.5 and 10, and
further agrees not to bring any action or proceeding arising out of or relating to this Agreement in any other court. Each of the
parties agrees that a final judgment in any action or proceeding so brought shall be conclusive and may be enforced by suit on
the judgment or in any other manner so provided by law.

 

		10.	Binding Arbitration

 

Except
as provided in Section 4.5, any and all disputes which involve or relate in any way to this Agreement and/or to Executive’s
employment, Executive's termination of employment with the Company or termination of this Agreement, whether initiated by Executive
or by the Company and whether based on contract, tort, statute, or common law, shall be submitted to and resolved by final and
binding arbitration as the exclusive method for resolving all such disputes. The arbitration shall be private and confidential
and conducted in Denver, Colorado pursuant to the Federal Arbitration Act and applicable Colorado law, and pursuant to the applicable
rules of the American Arbitration Association ("AAA") relating to employment disputes, unless the parties otherwise mutually
agree to modify the AAA Rules.

 

The
party demanding arbitration shall submit a written claim to the other party, setting out the basis of the claim or claims, within
the time period of any applicable statute of limitations relating to such claim(s). If the parties cannot mutually agree upon an
arbitrator, then the parties shall select a neutral arbitrator through the procedures established by the AAA. The arbitrator shall
have the powers provided under the Colorado Code of Civil Procedure relating to the arbitration of disputes, except as expressly
limited or otherwise provided in this Agreement. The parties shall have the right to reasonable discovery as mutually agreed or
as determined by the arbitrator, including at least one deposition each, it being the goal of the parties to resolve any disputes
as expeditiously and economically as reasonably practicable. The parties agree to share equally in the payment of the administration
costs of the AAA arbitration, including payment of the fees for the arbitrator, and any other costs directly related to the administration
of the arbitration. The parties shall otherwise be responsible for their own respective costs and attorneys' fees relating to the
dispute, such as deposition costs, expert witnesses and similar expenses, except as otherwise provided in this Agreement to the
prevailing party.

    	-11-

    	 

    

The
arbitrator may award, if properly proven, any damages or remedy that a party could recover in a civil litigation, and shall award
costs and reasonable attorneys' fees to the prevailing party. The award of the arbitrator shall be issued in writing, setting forth
the basis for the decision, and shall be binding on the parties to the fullest extent permitted by law, subject to any limited
statutory right to appeal as provided by law. Judgment upon the award of the arbitrator may be entered in any court having proper
jurisdiction and enforced as provided by law.

 

This
agreement to arbitrate is freely negotiated between Executive and the Company and is mutually entered into between the parties.
Each party understands and agrees that it is giving up certain rights otherwise afforded to it by civil court actions, including
but not limited to the right to a jury trial; provided, however, that either party may seek provisional remedies in a court of
competent jurisdiction as provided pursuant to applicable law.

 

		11.	Section Headings

 

The
section headings herein are inserted only as a matter of convenience and reference and in no way define, limit or describe the
scope of this Agreement or the intent of any provisions hereof.

 

		12.	Compliance with Section 409A of the Code

 

Notwithstanding
anything herein to the contrary, (a) if at the time of Executive's termination of employment with the Company Executive is a "specified
employee" as such term is defined in Section 409A of the Code and the regulations thereunder, and the deferral of the commencement
of any payments or benefits otherwise payable hereunder as a result of such termination of employment is necessary in order to
prevent any accelerated or additional tax under Section 409A of the Code, then the Company will defer the commencement of the
payment of any such payments or benefits hereunder (without any reduction in such payments or benefits ultimately paid or provided
to Executive) until the date that is six (6) months following Executive's termination of employment with the Company (or the earliest
date as is permitted under Section 409A of the Code) and (b) if any other payments of money or other benefits due to Executive
hereunder could cause the application of an accelerated or additional tax under Section 409A of the Code, such payments or other
benefits shall be deferred if deferral will make such payment or other benefits compliant under Section 409A of the Code, or otherwise
such payment or other benefits shall be restructured, to the extent possible, in a manner, determined by the Board, that does
not cause such an accelerated or additional tax. In the event that payments under this Agreement are deferred pursuant to this
Section 12 in order to prevent any accelerated tax or additional tax under Section 409A of the Code, then such payments shall
be paid at the time specified under this Section 12 without any interest thereon. The Company shall consult with Executive in
good faith regarding the implementation of this Section 12; provided that neither the Company nor any of its employees or representatives
shall have any liability to Executive with respect thereto. Notwithstanding anything to the contrary herein, a termination of
employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of amounts
or benefits upon or following a termination of employment unless such termination is also a "Separation from Service"
as such term is defined in Section 409A of the Code and the regulations and guidance promulgated thereunder and, for purposes
of any such provision of this Agreement, references to a "resignation," "termination," "termination of
employment," or like terms shall mean Separation from Service. For purposes of Section 409A of the Code, each payment made
under this Agreement shall be designated as a "separate payment" within the meaning of the Section 409A of the Code.
Notwithstanding anything to the contrary herein, except to the extent any expense, reimbursement or in-kind benefit provided pursuant
to this Agreement does not constitute a "deferral of compensation"
within the meaning of Section 409A of the Code: (x) the amount of expenses eligible for reimbursement or in-kind benefits provided
to Executive during any calendar year will not affect the amount of expenses eligible for reimbursement or in-kind benefits provided
to Executive in any other calendar year, (y) the reimbursements for expenses for which Executive is entitled to be reimbursed
shall be made on or before the last day of the calendar year following the calendar year in which the applicable expense is incurred,
and (z) the right to payment or reimbursement or in-kind benefits hereunder may not be liquidated or exchanged for any other benefit.

    	-12-

    	 

    

 

		13.	Entire Agreement

 

This
Agreement contains the entire agreement of the parties relating to the subject matter hereof, and this Agreement supersedes and
replaces in all respects the Original Agreement. Further, the parties hereto have made no agreements, representations, or warranties
relating to the subject matter of this Agreement that are not set forth otherwise herein. In this regard, each of the parties represents
and warrants to the other party that such party is not relying on any promises or representations that do not appear in writing
herein. Each of the parties further agrees and understands that this Agreement
can be amended or modified only by a written agreement signed by all parties.

 

		14.	Notice

 

All
notices required or permitted under this Agreement shall be in writing and shall be deemed effective: (a) upon delivery, if delivered
in person; (b) upon delivery to Federal Express or other similar courier service, marked for next day delivery,
addressed as set forth below; (c) upon deposit in United States Mail if sent by registered
or certified mail, return receipt requested, addressed as set forth below; or (d) upon being sent by facsimile transmission, provided
an original is mailed the same day by registered or certified mail, return receipt requested:

 

	If to the Company:	MusclePharm Corporation 
	 	Attn: Chief Executive Officer
	 	4721 Ironton Street, Building A 
	 	Denver, Colorado 80239
	 	Facsimile: (800) 490-7165
	 	 
	If to Executive:	Richard Estalella
	 	 	 
	 	  	 
	 	  	 

 

		15.	Attorneys' Fees

 

In
the event that any party shall bring an action or proceeding in connection with the performance, breach or interpretation of this
Agreement, then the prevailing party in any such action or proceeding, as determined by the arbitrator, court, or other body having
jurisdiction, shall be entitled to recover from the losing party all reasonable costs and expenses of such action or proceeding,
including reasonable attorneys'
fees, court costs, costs of investigation, expert witness fees, and other costs reasonably related to such action or proceeding.

    	-13-

    	 

    

 

		16.	Assistance with Claims

 

Executive
agrees that, for the period beginning on the Start Date, and continuing for a reasonable period after the termination or expiration
of this Agreement for any reason, Executive will assist the Company in the defense of any claims that may be made against the Company
and will assist the Company in the prosecution of any claims that may be made by the Company, to the extent such claims may relate
to services performed by Executive for the Company. Executive agrees to promptly inform the Company if Executive becomes aware
of any lawsuits or potential claims that may be filed against the Company. For all assistance occurring after termination of Executive's
employment by the Company, the Company agrees to provide reasonable compensation to Executive for such assistance. Executive also
agrees to promptly inform the Company if asked to assist in any investigation of the Company (or its actions) that may relate to
services performed by Executive for the Company, regardless of whether a lawsuit has been filed against the Company with respect
to such investigation.

 

		17.	Release of Claims

 

Executive
shall not be entitled to receive the severance pay and benefits under Sections 6.2, 6.3, and 6.4, as applicable, unless (a) Executive
executes and returns to the Company a Release (as defined below) on or before the 50th day following the date of termination or
such shorter time as may be prescribed in the Release, (b) such Release shall not have been timely revoked
by Executive, and (c) the date of termination constitutes a Separation from Service, and provided
further, however, that if Executive violates his continuing obligations under Sections 4.1 , 4.2, 4.3, or 4.4, Executive shall
not be entitled to receive such severance pay or benefits and Executive shall immediately repay to the Company upon written demand
any severance pay or benefits that already have been paid to Executive. For purposes of this Agreement, the term "Release"
means a waiver and release of claims by Executive in the form prescribed by the Company, which form may include, without limitation,
an agreement by Executive not to disparage the Company, its affiliates, and other related persons or entities, but which form shall
not include a release and waiver of claims for (i) indemnification or for coverage under officer and director liability policies,
if applicable, (ii) claims with respect to the reimbursement of business expenses or with respect to benefits which are in each
case to continue in effect after termination or expiration of this Agreement in accordance with the terms of this Agreement, (iii)
claims he may have as a holder of options to acquire equity securities of the Company (which shall be governed by the documents
by which Executive was granted such options) and (iv) claims he may have as a stockholder of the Company.

 

		18.	Dodd-Frank Act and Other
Applicable Legal Requirements

 

Executive
agrees (i) to abide by any compensation recovery, recoupment, anti-hedging, or other policy applicable to executives of the Company
and its affiliates, as may be in effect from time to time, as approved by the Board or a duly authorized committee thereof or as
required by the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the "Dodd-Frank Act") or other
applicable law, and (ii) that the terms and conditions of this Agreement shall be deemed automatically amended as may be necessary
from time to time to ensure compliance by Executive and this Agreement with such policies, the Dodd-Frank Act, or other applicable
law.

 

    	-14-

    	 

    

		19.	Counterparts

 

This Agreement
may be executed in any number of counterparts, each of which shall be deemed to be an original, but all of which together shall
constitute but one and the same instrument.

 

 

 

 

EXECUTIVE
HAS BEEN ADVISED THAT HE SHOULD SEEK INDEPENDENT REVIEW AND ADVICE FROM LEGAL COUNSEL AND TAX ADVISORS AS TO THE SCOPE AND POTENTIAL
TAXES WH ICH COULD ARISE FROM THE AGREEMENT.

 

(Signature Page
Follows)

    	-15-

    	 

    

 

IN WITNESS WHEREOF, this Agreement is executed
as of the day and year first above written.

 

	 	MusclePharm Corporation
	 	 	 
	 	 	 
	 	By:	/s/ Brad Pyatt	 
	 	 	Name: Brad Pyatt
	 	 	Title: CEO
	 	 	 
	 	 	 
	 	 	 
	 	Executive
	 	 	 
	 	By:	/s/ Richard Estalella	 
	 	 	Name:

 

 

    	-16-EXHIBIT 10.1

 

[FORM OF]

FIRST AMENDMENT TO 

NILE THERAPEUTICS, INC.

SECURED CONVERTIBLE PROMISSORY NOTES

 

This FIRST AMENDMENT
TO NILE THERAPEUTICS, INC. SECURED CONVERTIBLE PROMISSORY NOTES (this “First Amendment”) is made and entered
into as of March 15, 2013, by and between NILE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and
the undersigned holders (each a “Holder” and together the “Holders”) of Nile Therapeutics,
Inc. Secured Convertible Promissory Notes (each a “Note” and collectively the “Notes”) issued
and sold by the Company pursuant to that certain Convertible Note Purchase Agreement, dated as of March 15, 2013 (the “Note
Purchase Agreement”), by and among the Company and the purchasers named therein (the “Purchasers”).

 

W I T N E S S E T H:

 

WHEREAS, the Company
issued and sold to the Purchasers, and the Purchasers purchased from the Company, an aggregate of $450,000 principal amount of
Notes pursuant to the Note Purchase Agreement;

 

WHEREAS, Section 5
of the Notes provides that the terms of the Notes may only be amended, modified or waived by the written consent of the Company
and the Purchasers purchasing at least two-thirds (2/3) of the principal amount of the Notes (the “Requisite Purchasers”);

 

WHEREAS, the Company
and the Requisite Purchasers desire to amend the Notes to provide (a) in the event of a Change of Control (as defined in the Notes),
that the conversion price be equal to the average VWAP of the Company’s common stock for each trading day during the period
commencing on July 8, 2013, the date of the announcement of the Change of Control, through the earlier of (i) September 30, 2013,
and (ii) the date of the consummation of the Change of Control; (b) for the agreement by the Purchasers to release all Released
Claims (as defined below) which each such Purchaser may have now, have had, or hereafter have against the Company; and (c) for
an acknowledgement by the Purchasers that the general security interest in the Company’s assets granted by the Security Agreement
(as defined below) will terminate at conversion of the Notes upon a Change of Control; and

 

WHEREAS, the Company
and the Requisite Purchasers desire to further amend the Notes to provide that during the Lock-Up Period (as defined below), none
of the Holders shall sell, transfer or otherwise dispose of any shares of the Company’s common stock, or any of the voting
or economic interests with respect thereto.

 

NOW, THEREFORE, in
consideration of the mutual agreements, provisions and covenants contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

 

SECTION 1.          Defined
Terms. Capitalized terms used herein (including in the preamble and recitals above) but not otherwise defined herein shall
have the respective meanings ascribed to such terms in the Notes.

 

    	1

    	 

    

 

SECTION 2.          Amendment
to Section 2(a) of the Notes. Section 2(a) of each of the Notes is hereby deleted in its entirety and replaced with
the following:

 

(a) Upon a Change of
Control (as defined below) in which either (i) the outstanding shares of the Company’s common stock are exchanged for securities
of another corporation, or (ii) the Company issues shares of its common stock, with no securities or other consideration paid or
payable to holders of the Company’s common stock (e.g., a merger transaction in which the Company acquires another corporation
in exchange for shares of the Company’s common stock), then (A) the entire unpaid principal under the Note shall automatically
convert, as of immediately prior to the effective time of the Change of Control, into shares of the Company’s common stock
(the “Mandatory Conversion Shares,” and together with the Optional Conversion Shares, the “Conversion
Shares”) at a conversion price per share equal to the average VWAP of the Company’s common stock for each trading
day during the period commencing on July 8, 2013, the date of the announcement of the Change of Control, through the earlier of
(i) September 30, 2013, and (ii) the date of the consummation of the Change of Control (the “Mandatory Conversion Price”),
and (B) the Company shall also issue to the Holder a five-year warrant, in substantially the form of Exhibit A hereto, entitling
the Lender to purchase, at an exercise price equal to the Mandatory Conversion Price, that number of shares of the Company’s
common stock (the “Warrant Shares”) obtained by dividing (a) the sum of the outstanding principal hereunder
by (b) the Mandatory Conversion Price.

 

SECTION 3.          Addition
of Section 2(e) to the Notes. A new Section 2(e) is hereby added to each of the Notes, which reads as follows:

 

(e) As used herein, the
term “VWAP” shall mean the dollar volume-weighted average price for the Company’s common stock on the
OTC Bulletin Board (or, if the OTC Bulletin Board is not the principal trading market for the Company’s common stock, then
on the principal securities exchange or securities market on which the Company’s common stock is then traded) during the
period beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg through its
“Volume at Price” function or, if the foregoing does not apply, the dollar volume-weighted average price of the Company’s
common stock in the over-the-counter market on the electronic bulletin board for the Company’s common stock during the period
beginning at 9:30:01 a.m., New York time, and ending at 4:00:00 p.m., New York time, as reported by Bloomberg, or, if no dollar
volume-weighted average price is reported for the Company’s common stock by Bloomberg for such hours, the average of the
highest closing bid price and the lowest closing ask price of any of the market makers for the Company’s common stock as
reported in the “pink sheets” by Pink Sheets LLC (or a similar organization or agency succeeding to its functions of
reporting prices). If there is zero trading volume for any day during the computation period, such days will be excluded from the
computation of average VWAP. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock
combination or other similar transaction during such period.

 

 

    	2

    	 

    

SECTION 4.          Addition
of Section 13 to the Notes. A new Section 13 is hereby added to each of the Notes, which reads as follows:

 

13.          Agreement to Release Claims.

 

(a) The Holder, on behalf
of himself, herself or itself and on behalf of his, her or its legal representatives, permitted assigns and beneficiaries (the
“Related Persons”), hereby releases and forever discharges the Company and each successor to the Company, including
each of their respective individual, joint or mutual, past, present and future representatives, affiliates, officers, directors,
stockholders, controlling persons, attorneys, subsidiaries, successors and assigns (individually, a “Releasee”
and collectively, “Releasees”), from any and all claims, demands, legal proceedings, causes of action, orders,
obligations, contracts, debts and liabilities whatsoever, whether known or unknown, both at law and in equity, which the Holder
now has, has ever had or may hereafter have against the respective Releasees related to or arising in connection with the Mandatory
Conversion Price contained in the Notes prior to the execution of this First Amendment, any and all other agreements, oral or written,
whether or not executed or delivered, or promised to be executed or delivered, and all representations or promises made in connection
therewith (collectively, the “Released Claims”). For purposes of clarity, the right to receive the Mandatory
Conversion Shares is not released hereby and does not constitute “Released Claims” hereunder.

 

(b) The Holder, on behalf
of himself, herself or itself and on behalf of his, her or its Related Persons, hereby irrevocably covenants to refrain from, directly
or indirectly, asserting any Released Claim, or commencing, instituting or causing to be commenced, any legal proceeding of any
kind against any Releasee, based upon any matter purported to be released hereby. Notwithstanding the foregoing, nothing contained
herein shall prevent the Holder (or his, her or its Related Person) from defending himself, herself or itself against any Released
Claim brought against the Holder (or his, her or its Related Person) by any Releasee, including by bringing a counterclaim against
any Releasee.

 

(c) Notwithstanding anything
to the contrary contained in the Note Purchase Agreement or that certain Security Agreement, dated as of March 15, 2013, by and
among the Company and the creditors identified therein, which includes all the Purchasers (the “Security Agreement”),
the Holder expressly acknowledges and agrees that, upon a Change of Control and conversion of this Note in accordance with Section
2(a) of this Note, (i) all obligations of the Company under this Note shall be deemed satisfied in full, (ii) the general security
interest in the Company’s assets granted by the Security Agreement shall terminate and be deemed released in all respects,
and (iii) the Company is authorized to make any filings terminating that certain financing statement under the Uniform Commercial
Code filed with the Secretary of State of the State of Delaware on or about March 18, 2013.

 

SECTION 5.          Addition
of Section 14 to the Notes. A new Section 14 is hereby added to each of the Notes, which reads as follows

 

14.          Waiver of
Unknown Claims. With respect to the Released Claims described in Section 13 above, the Holder expressly waives any and
all rights under Section 1542 of the California Civil Code, and any like provision or principal of state law, common law in any
foreign jurisdiction or under federal law. The Holder has read Section 1542 of the Civil Code of the State of California, which
provides as follows:

 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH
THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM
OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

 

 

    	3

    	 

    

 

SECTION 6.          Addition
of Section 15 to the Notes. A new Section 15 is hereby added to each of the Notes, which reads as follows:

 

15.          Lock-Up
Agreement.

 

(a) The Holder hereby
irrevocably agrees that the Holder will not (and will cause any spouse or family member of the spouse of the Holder, any partnership,
corporation or other entity within the Holder’s control, and any trustee or any trust that holds or will hold the Company’s
common stock or other securities of the Company for the benefit of the Holder or such spouse or family member not to), without
the prior written consent of the Company, directly or indirectly: (i) offer for sale, pledge, hypothecate, encumber, lend, sell,
contract to sell, make any short sale, establish an open “put equivalent position” within the meaning of Rule 16a-1(h)
under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), liquidate or decrease any “call
equivalent position” within the meaning of Section 16 of the Exchange Act, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase or otherwise assign, tender, transfer or dispose
of (or enter into any transaction or device that is designed to, or could be expected to, result in the disposition by any person
at any time in the future of), any shares of the Company’s common stock, including any securities of the Company issued or
issuable upon exercise, conversion or exchange of any shares of the Company’s common stock (“Company Common Shares”),
including any Company Common Shares that may be deemed to be beneficially owned by the Holder in accordance with the rules and
regulations of the United States Securities and Exchange Commission, (ii) enter into any swap, hedge or other derivatives transaction
that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of Company Common Shares, whether
any such transaction described in clause (i) or (ii) above is to be settled by delivery of Company Common Shares or other securities,
in cash or otherwise, or (iii) publicly disclose the intention to do any of the foregoing with respect to any Company Common Shares,
in each case, from the date of this First Amendment until the earlier of (i) September 30, 2013, and (ii) the date following the
consummation of the Change of Control  (the “Lock-Up Period”).  

 

(b) In furtherance of
Section 15(a), the Holder hereby authorizes the Company and the Company’s transfer agent on the Company’s behalf to
(i) enter stop transfer restrictions on the transfer books and records of the Company with respect to Company Common Shares, and
(ii) decline to make any transfer of securities if such transfer would constitute a violation or breach of this Note or the Note
Purchase Agreement. The Holder further agrees that, upon request of the Company, the Holder will execute any additional documents
necessary in connection with the enforcement of this Section 15.

 

    	4

    	 

    

 

(c) Notwithstanding the
foregoing subsections (a) and (b), and subject to the conditions below, the Holder may transfer Company Common Shares in the transactions
described in clauses (i) through (iv) below without the prior written consent of the Company; provided that (1) the Company receives
a signed lock-up agreement, in a form satisfactory to the Company, for the balance of the Lock-Up Period from each donee, trustee,
distributee or transferee, as the case may be, and (2) any such transfer shall not involve a disposition for value: (i) as a bona
fide gift or gifts; (ii) to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder; (iii)
to any beneficiary of the Holder pursuant to a will or other testamentary document or applicable laws of descent; or (iv) to a
corporation of which a majority of the issued and outstanding shares of such corporation are owned by the Holder.

 

(d) The Holder acknowledges
that any sale or other transfer or disposition of any Company Common Shares in violation of this Section 15 will be null and void.
The Holder further acknowledges that it is impossible to measure the damages that will accrue to the Company by reason of a failure
of the Holder to comply with the terms of this Section 15. Therefore, if the Company shall institute any action or proceeding to
enforce the provisions hereof, the Holder agrees that the Company shall be entitled to injunctive relief (without the necessity
of posting a bond), and the Holder waives, and shall not allege, any claim or defense that the Holder has an adequate remedy at
law.

 

SECTION 7.           Amendment
to Exhibit A. Exhibit A to each of the Notes is hereby amended and restated in its entirety and replaced by Exhibit
A attached hereto.

 

SECTION 8.           Captions.
Captions used in this First Amendment are for convenience only and shall not affect the construction of this First Amendment.

 

SECTION 9.           Counterparts.
This First Amendment may be executed in any number of counterparts and by the different parties hereto on separate counterparts
and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute but one and the
same First Amendment. Receipt by facsimile or other electronic transmission of any executed signature page to this First Amendment
shall constitute effective delivery of such signature page.

 

SECTION 10.        Severability.
Any provision of this First Amendment that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be
ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any
such prohibition or unenforceability in any jurisdiction shall (to the full extent permitted by law) not invalidate or render unenforceable
such provision in any other jurisdiction.

 

SECTION 11.        Entire
Agreement. Each of the Notes, as amended hereby, together with the Note Purchase Agreement as amended hereby, embodies
the entire agreement and understanding among the parties hereto and supersedes all prior or contemporaneous agreements and understandings
of such parties, verbal or written, relating to the subject matter hereof and thereof.

 

    	5

    	 

    

 

SECTION 12.        Successors;
Assigns. All covenants and other agreements contained in this First Amendment by or on behalf of any of the parties hereto
bind and inure to the benefit of their respective permitted successors and permitted assigns (including, without limitation, any
subsequent holder of a Note) whether so expressed or not.

 

SECTION 13.        Governing
Law. This First Amendment shall be governed by, and construed and enforced in accordance with, the laws of the State of
Delaware, without giving effect to the principles of conflict of laws.

 

SECTION 14.        Reaffirmation.
Each of the Company and the Purchasers hereby ratifies and reaffirms all of its payment and performance obligations, contingent
or otherwise, under the Notes (after giving effect hereto) and the Note Purchase Agreement. Each of the Company and the Requisite
Purchasers hereby consents to this First Amendment and acknowledges that each of the Notes, as amended hereby and the Note Purchase
Agreement, remains in full force and effect and is hereby ratified and reaffirmed.

 

 

 

 

[Remainder of page intentionally left
blank; signature page follows]

 

    	6

    	 

    

Each of the undersigned
has caused this First Amendment to be duly executed and delivered as of the date first above written.

 

 

	 	COMPANY:	 
	 	 	 
	 	NILE THERAPEUTICS, INC.	 
	 	 	 
	 	 	 
	 	By:	 	 
	 	 	 
	 	Name:	 	 
	 	 	 
	 	Title:	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	HOLDER	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	Name:	 	 
	 	 	 
	 	 	 
	 	Principal Amount of Notes Held	 

 

 

 

[Signature Page to First Amendment to
Notes]

    	 

    	 

    

Exhibit A

 

THE SECURITIES REPRESENTED HEREBY AND
ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR
UNDER THE SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND
MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO
REGISTRATION UNDER SUCH LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED
TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN
OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE
WITH THE SECURITIES ACT AND ALL APPLICABLE STATE SECURITIES LAWS.

 

NILE THERAPEUTICS, INC.

 

[FORM OF] AMENDED AND RESTATED WARRANT
TO PURCHASE COMMON STOCK

 

	Warrant No. [2013-XX]	 	Original Issue Date: [DATE]1

 

Nile Therapeutics,
Inc., a Delaware corporation (the “Company”), hereby certifies that, for value received, [_______________]
or its permitted registered assigns (the “Holder”), is entitled to purchase from the Company up to a total of
[________________] ([_____]) shares of common stock, $0.001 par value (the “Common Stock”), of the Company (each
such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price
per share equal to $[__]2 (as adjusted
from time to time as provided in Section 9 herein, the “Exercise Price”), at any time and from time to time
from on or after the date hereof (the “Trigger Date”) and through and including 5:30 P.M., New York City time,
on [DATE]3 (the “Expiration
Date”), and subject to the following terms and conditions:

 

This Amended and Restated
Warrant (this “Warrant”) is one of a series of similar warrants issued pursuant to that certain Convertible
Note Purchase Agreement dated March 15, 2013, by and among the Company and the Purchasers identified therein (the “Purchase
Agreement”). All such warrants are referred to herein, collectively, as the “Warrants.”

 

 

 

1
To be issued upon a Change of Control, as described in Section 2(a) of the NileTherapeutics, Inc. Secured Convertible Promissory
Note as amended by the First Amendment thereto.

2
The Exercise Price shall be the Mandatory Conversion Price as defined in the NileTherapeutics, Inc. Secured Convertible Promissory
Note as amended by the First Amendment thereto.

3
Expiration Date shall be the five-year anniversary of the Original Issue Date.

    	 

    	 

    

 

 

1.            Definitions.
In addition to the terms defined elsewhere in this Warrant, capitalized terms that are not otherwise defined herein have the meanings
given to such terms in the Purchase Agreement.

 

2.            Registration
of Warrants. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant
Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any registered
assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered
Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and
for all other purposes, absent actual notice to the contrary.

 

3.            Registration
of Transfers. Subject to the restrictions on transfer set forth in Article 4 of the Purchase Agreement and compliance with
all applicable securities laws, the Company shall register the transfer of all or any portion of this Warrant in the Warrant Register,
upon (i) surrender of this Warrant, with the Form of Assignment attached as Schedule 2 hereto duly completed and signed,
to the Company’s transfer agent or to the Company at its address specified herein and (ii) if the Registration Statement
is not effective, (x) delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory to the Company
to the effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from the registration
requirements of the Securities Act and all applicable state securities or blue sky laws and (y) delivery by the transferee of a
written statement to the Company making the representations and certifications set forth in Article 4 of the Purchase Agreement,
to the Company at its address specified in the Purchase Agreement. Upon any such registration or transfer, a new warrant to purchase
Common Stock in substantially the form of this Warrant (any such new warrant, a “New Warrant”) evidencing the
portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of
this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee
thereof shall be deemed the acceptance by such transferee of all of the rights and obligations of a Holder of a Warrant.

 

4.            Exercise
and Duration of Warrants.

 

(a)          All
or any part of this Warrant shall be exercisable by the registered Holder at any time and from time to time on or after the Trigger
Date and through and including 5:30 P.M. New York City time on the Expiration Date. At 5:30 P.M., New York City time, on the Expiration
Date, the portion of this Warrant not exercised prior thereto shall be and become void and of no value and this Warrant shall be
terminated and no longer outstanding;

 

(b)          The
Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as Schedule 1
hereto (the “Exercise Notice”), appropriately completed and duly signed and (ii) payment of the Exercise Price
in immediately available funds for the number of Warrant Shares as to which this Warrant is being exercised, and the date such
items are delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise Date.”
The delivery by (or on behalf of) the Holder of the Exercise Notice and the applicable Exercise Price as provided above shall constitute
the Holder’s certification to the Company that its representations contained in Article 4 of the Purchase Agreement are true
and correct as of the Exercise Date as if remade in their entirety (or, in the case of any transferee Holder that is not a party
to the Purchase Agreement, such transferee Holder’s certification to the Company that such representations are true and correct
as to such assignee Holder as of the Exercise Date). The Holder shall not be required to deliver the original Warrant in order
to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the
original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares.

  

    	 

    	 

    

 

5.            Delivery
of Warrant Shares. Upon exercise of this Warrant, the Company shall promptly (but in no event later than three trading days
after the Exercise Date) issue or cause to be issued and cause to be delivered to or upon the written order of the Holder and in
such name or names as the Holder may designate (provided that, if the Registration Statement is not effective and the Holder directs
the Company to deliver a certificate for the Warrant Shares in a name other than that of the Holder, it shall deliver to the Company
on the Exercise Date an opinion of counsel reasonably satisfactory to the Company to the effect that the issuance of such Warrant
Shares in such other name may be made pursuant to an available exemption from the registration requirements of the Securities Act
and all applicable state securities or blue sky laws), a certificate for the Warrant Shares issuable upon such exercise, free of
restrictive legends, unless a registration statement covering the resale of the Warrant Shares and naming the Holder as a selling
stockholder thereunder is not then effective or the Warrant Shares are not freely transferable pursuant to Rule 144 under the Securities
Act pursuant to transactions in which paragraph (c)(1) of such rule do not apply. The Holder, or any person permissibly so designated
by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise
Date. If the Warrant Shares are to be issued free of all restrictive legends, the Company shall, upon the written request of the
Holder, use its best efforts to deliver, or cause to be delivered, Warrant Shares hereunder electronically through The Depository
Trust Company or another established clearing corporation performing similar functions, if available; provided, that, the Company
may, but will not be required to, change its transfer agent if its current transfer agent cannot deliver Warrant Shares electronically
through such a clearing corporation.

 

6.            Charges,
Taxes and Expenses. Issuance and delivery of certificates for shares of Common Stock upon exercise of this Warrant shall be
made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense in respect
of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that
the Company shall not be required to pay any tax which may be payable in respect of any transfer involved in the registration of
any certificates for Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all
other tax liability that may arise as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise
hereof.

 

7.            
Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be
issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant,
but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and,
in each case, a customary and reasonable indemnity (which shall not include a surety bond), if requested. Applicants for a New
Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable
third-party costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation of this Warrant, then
the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company’s obligation to issue
the New Warrant.

  

    	 

    	 

    

 

8.            
Reservation of Warrant Shares. The Company covenants that it will at all times reserve and keep available out of the aggregate
of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares
upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon the
exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the
Holder (taking into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares
so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms
hereof, be duly and validly authorized, issued and fully paid and nonassessable. The Company will take all such action as may be
necessary to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or
regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Shares may be
listed.

 

9.            Certain
Adjustments. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment
from time to time as set forth in this Section 9.

 

(a)          Stock
Dividends and Splits. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on its Common
Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides
its outstanding shares of Common Stock into a larger number of shares, or (iii) combines its outstanding shares of Common Stock
into a smaller number of shares, then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of
which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall
be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made pursuant to clause (i) of
this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution, and any adjustment pursuant to clause (ii) or (iii) of this paragraph shall become effective immediately
after the effective date of such subdivision or combination.

 

    	 

    	 

    

 

(b)          
Fundamental Transactions. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation
of the Company with or into another person, in which the shareholders of the Company as of immediately prior to the transaction
own less than a majority of the outstanding stock of the surviving entity, (ii) the Company effects any sale of all or substantially
all of its assets or a majority of its Common Stock is acquired by a third party, in each case, in one or a series of related transactions,
(iii) any tender offer or exchange offer (whether by the Company or another person) is completed pursuant to which all or substantially
all of the holders of Common Stock are permitted to tender or exchange their shares for other securities, cash or property and
would result in the shareholders of the Company immediately prior to such tender offer or exchange offer owning less than a majority
of the outstanding stock after such tender offer or exchange offer, or (iv) the Company effects any reclassification of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section
9(a) above) (in any such case, a “Fundamental Transaction”), then the Holder shall have the right thereafter
to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled
to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction,
the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (the “Alternate Consideration”).
The Company shall not effect any such Fundamental Transaction unless prior to or simultaneously with the consummation thereof,
any successor to the Company, surviving entity or the corporation purchasing or otherwise acquiring such assets or other appropriate
corporation or entity shall assume the obligation to deliver to the Holder, such Alternate Consideration as, in accordance with
the foregoing provisions, the Holder may be entitled to purchase and/or receive (as the case may be), and the other obligations
under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent transactions analogous to a Fundamental
Transaction.

 

(c)          Number
of Warrant Shares. Simultaneously with any adjustment to the Exercise Price pursuant to Subparagraph 9(a), the number
of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that
after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall
be the same as the aggregate Exercise Price in effect immediately prior to such adjustment.

 

(d)          Calculations.
All calculations under this Section 9 shall be made to the nearest cent or the nearest 1/100th
of a share, as applicable. The number of shares of Common Stock outstanding at any given time shall not include shares owned or
held by or for the account of the Company, and the sale or issuance of any such shares shall be considered an issue or sale of
Common Stock. 

 

(e)           Notice
of Adjustments. Upon the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will,
at the written request of the Holder, compute such adjustment, in good faith, in accordance with the terms of this Warrant and
prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or
type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions
giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the
Company will deliver a copy of each such certificate to the Holder and to the Company’s transfer agent.

 

10.           Payment
of Exercise Price. The Holder shall pay the Exercise Price in immediately available funds.

 

    	 

    	 

    

 

11.      
    No Fractional Shares. No fractional Warrant Shares will be issued in connection with any exercise
of this Warrant. In lieu of any fractional shares which would otherwise be issuable, the number of Warrant Shares to be issued
shall be rounded to the nearest whole number.

 

12.           Notices.
Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall
be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number specified in the Purchase Agreement prior to 5:30 p.m. (New York City time)
on a trading day, (ii) the next trading day after the date of transmission, if such notice or communication is delivered via facsimile
at the facsimile number specified in the Purchase Agreement on a day that is not a trading day or later than 5:30 p.m. (New York
City time) on any trading day, (iii) the trading day following the date of mailing, if sent by nationally recognized overnight
courier service specifying next business day delivery, or (iv) upon actual receipt by the party to whom such notice is required
to be given, if by hand delivery. The address and facsimile number of a party for such notices or communications shall be as set
forth in the Purchase Agreement unless changed by such party by two trading days’ prior notice to the other party in accordance
with this Section 12.

 

13.      
    Warrant Agent. The Company shall serve as warrant agent under this Warrant. Upon thirty (30) days’
notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent
may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party
or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders
services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent
shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder
at the Holder’s last address as shown on the Warrant Register.

 

14.           Miscellaneous.
 

 

(a)          The
Holder, solely in such person's capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be
deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to
confer upon the Holder, solely in such person’s capacity as the Holder of this Warrant, any of the rights of a stockholder
of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends
or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such person is then entitled
to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing
any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the
Company, whether such liabilities are asserted by the Company or by creditors of the Company. Notwithstanding this Section 15(a),
the Company shall provide the Holder with copies of the same notices and other information given to the shareholders of the Company,
contemporaneously with the giving thereof to the shareholders.

 

    	 

    	 

    

 

(b)          Subject
to the restrictions on transfer set forth on the first page hereof and in Article 4 of the Purchase Agreement, and compliance with
applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company except
to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit of the parties
hereto and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed
to give to any person other than the Company and the Holder any legal or equitable right, remedy or cause of action under this
Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns.

 

(c)          Governing
Law. This Warrant shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without
giving effect to the principles of conflict of laws.

 

(d)          Waiver
of Jury Trial. EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT
OF THIS NOTE OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES
THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT
CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION
HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO
HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY
AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.

 

(e)          The
headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any
of the provisions hereof.

 

(f)           In
case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability
of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the parties will
attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor,
and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

(g)           Except
as otherwise set forth herein, prior to exercise of this Warrant, the Holder hereof shall not, by reason of by being a Holder,
be entitled to any rights of a stockholder with respect to the Warrant Shares.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,

SIGNATURE PAGE FOLLOWS]

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the Company has caused
this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

 

	 	
        NILE THERAPEUTICS, INC.

         

	 	 	 
	 	By:	  	 
	 	 	Name:
	 	 	Title:

 

 

    	 

    	 

    

SCHEDULE 1

 

FORM OF EXERCISE NOTICE

 

(To be executed by the Holder to exercise
the right to purchase shares

of Common Stock under the foregoing Warrant)

 

To:        Nile Therapeutics,
Inc.

 

(1)         The
undersigned is the Holder of Warrant No. [2013-XX] (the “Warrant”) issued by Nile Therapeutics, Inc. a Delaware corporation
(the “Company”). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth
in the Warrant.

 

(2)         The
undersigned hereby exercises its right to purchase __________ Warrant Shares pursuant to the Warrant.

  

(3)         The
Holder shall pay the sum of $_______ in immediately available funds to the Company in accordance with the terms of the Warrant.

 

(4)         Pursuant
to this Exercise Notice, the Company shall deliver to the Holder _____________ Warrant Shares in accordance with the terms of the
Warrant.

 

Dated: _______________, _____

 

	Name of Holder:  	 	 

 

	By:	 	 
	Name: 	 	 
	Title:	 	 
	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)	 

    	 

    	 

    

SCHEDULE 2

 

NILE THERAPEUTICS, INC.

 

FORM OF ASSIGNMENT

[To be completed and signed only upon transfer
of Warrant]

 

FOR VALUE RECEIVED, the undersigned hereby
sells, assigns and transfers unto _____________ (the “Transferee”) the right represented by the within Warrant to purchase
_______ shares of Common Stock of Nile Therapeutics, Inc. (the “Company”) to which the within Warrant relates and appoints
_________________ attorney to transfer said right on the books of the Company with full power of substitution in the premises.
In connection therewith, the undersigned represents, warrants, covenants and agrees to and with the Company that:

 

		(a)	the offer and sale of the Warrant contemplated hereby is being made in compliance with Section
4(1) of the United States Securities Act of 1933, as amended (the “Securities Act”) or another valid exemption from
the registration requirements of Section 5 of the Securities Act and in compliance with all applicable securities laws of the states
of the United States;

 

		(b)	the undersigned has not offered to sell the Warrant by any form of general solicitation or general
advertising, including, but not limited to, any advertisement, article, notice or other communication published in any newspaper,
magazine or similar media or broadcast over television or radio, and any seminar or meeting whose attendees have been invited by
any general solicitation or general advertising;

 

		(c)	the undersigned has read the Transferee’s investment letter included herewith, and to its
actual knowledge, the statements made therein are true and correct; and

 

		(d)	the undersigned understands that the Company may condition the transfer of the Warrant contemplated
hereby upon the delivery to the Company by the undersigned or the Transferee, as the case may be, of a written opinion of counsel
(which opinion shall be in form, substance and scope customary for opinions of counsel in comparable transactions) to the effect
that such transfer may be made without registration under the Securities Act and under applicable securities laws of the states
of the United States.

 

	Dated: 	 	 	 
	 	 	 	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
	
         
	
         

         

        
	 	
         

        Address of Transferee: 

	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

	In the presence of:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]